Hornet Therapeutics, a London, UK-based biotech company, raised seed funding from 4BIO Capital. The company emerged from stealth with a strategic collaboration and licensing agreement with Kyowa Kirin to develop and commercialize HTX-201 in EBV-related diseases. The amount of the deal was not disclosed.

4 Bio Capital

Hornet Therapeutics is a London, UK-based biotech company focused on developing treatments to address EBV-driven pathologies. The company emerged from stealth with a strategic collaboration and licensing agreement with Kyowa Kirin, enabling them to develop and commercialize HTX-201 in EBV-related diseases.

Hornet Therapeutics raised seed funding from 4BIO Capital to develop treatments for EBV-driven pathologies

Investors

Description

Company Information

Related People

Funding Insights

Hornet Therapeutics raised seed funding from 4BIO Capital to develop treatments for EBV-driven pathologies

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information